Compare GSK plc (GSK) vs Schlumberger NV (SLB) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

SLB trades at $47.21, down 0.69% on the day, with a bullish technical signal supported by moving averages. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $0.52. Recent strategic alliances with Liberty Energy for data center power solutions and major contract wins like the Baleine Phase 3 EPC deal highlight growth initiatives. Valuation metrics show a P/E of 20.95 and P/S of 1.95, while profitability remains solid with a net income margin of 9.26% and ROE of 14.57%.

The outlook for SLB is positive, driven by contract expansions and diversification into data center infrastructure, offering upside to the $62.83 consensus price target. Risks include oil price volatility and execution challenges in new ventures. Analyst sentiment is strongly bullish with 84.85% buy ratings, though investors should monitor debt levels and macroeconomic pressures on energy demand.